Computer-Automated, Time-Lapse Embryo Photography May Increase Success of In-Vitro Fertilization
New Technology May Allow Doctors to Select Embryos with Greater Chance of Developing Into a Viable Pregnancy
Source Newsroom: Perelman School of Medicine at the University of Pennsylvania
Newswise — PHILADELPHIA - Using computer-automated, time‐lapse photography of embryos in the laboratory during in-vitro fertilization may improve embryo selection, potentially increasing the chances of pregnancy among women undergoing the procedure, according to new research from the Perelman School of Medicine at the University of Pennsylvania and five other fertility centers. Results of the study were presented this week at the 30th annual European Society of Human Reproduction and Embryology (ESHRE) meeting in Munich, Germany.
The researchers at Penn and their collaborators used the Early Embryo Viability Assessment imaging device (or Eeva, developed and manufactured by Auxogyn, Inc.), which records images of developing embryos during the first three days of laboratory culture, to evaluate embryos transferred into the uterine cavity of 177 patients. The testing process involved fitting the devices into a standard incubator and using dark field imaging to capture high resolution, single-plane pictures of embryos housed in a petri dish, at five-minute intervals. The images were then fed into a software program that uses several measures to assess the embryo’s developmental potential – rating them high, medium, or low for their capacity to reach the blastocyst stage by the fifth or sixth day of culture. Embryos normally implant at the blastocyst stage – when they have divided into about 100-200 cells – and it is and it is known that blastocysts have a much greater chance of implanting successfully and resulting in an ongoing, viable pregnancy.
Information on the embryo quality rating was not available to clinicians during the IVF procedures that were part of the study, but when researchers unblinded the study results, they found that patients with at least one “high” rated embryo transferred had a 54 percent viable pregnancy rate compared to a 34 percent rate for those following transfer of only a “low” rated embryo.
“Our findings provide promising news for couples using or considering in-vitro fertilization because it shows that this technology offers the prospect of selecting embryos that have a greater likelihood of resulting in a pregnancy,” said lead author Matthew VerMilyea, PhD, who was serving as director of Assisted Reproductive Technologies and Andrology Laboratories at Penn at the time of the study and is currently a consultant to the division of Reproductive Endocrinology at Penn Medicine. “What’s particularly important is that our participants are from multiple clinics, each with distinctive protocols and patient populations, indicating that this technology may be generalizable and could have a significant impact in widely different laboratory settings.”
After an egg has been fertilized by a sperm, normal embryos follow clear-cut timeframes for development, such as the time it takes for a two-cell embryo to turn into a three-cell embryo, and the time it takes for a three-cell embryo to turn into a four-cell embryo. Based on these patterns, computer-automated programs have the potential to predict by day two of embryo development which embryo(s) are more likely to become viable blastocysts and, as suggested by the current Penn study, result in a viable pregnancy. By using non-invasive cell tracking and prediction software, the development of each embryo is automatically analyzed against the well-validated cell division time periods. If the timing and duration of cellular divisions fall within the defined optimal time periods, an embryo is given a high probability rating for becoming a blastocyst. If division timing falls outside of the optimal time range, an embryo is given a low probability rating. The current study extends these findings by showing that embryos receiving a high rating for becoming a blastocyst, also have a higher probability to implant and result in a viable pregnancy.
At present, fertility experts examine embryos under a microscope, looking at potential indicators of health of the embryo such as the number and symmetry of cells, and degrees of cell fragmentation. Based on these assessments and following recommendations developed through observational and correlative studies, clinicians and their embryology colleagues then choose which embryo(s) to transfer to the womb. The time-lapse system used in the new study uses objective visual evidence and automated predictive algorithms to enhance this conventional approach.
“Improving our ability to predict which embryos are most likely to result in pregnancy has been an elusive but sorely needed advance in the field of assisted reproduction” said Christos Coutifaris, MD, PhD, chief of Reproductive Endocrinology at the Perelman School of Medicine at the University of Pennsylvania. “However, there is the potential for one more major breakthrough for this technology: By developing better, non-invasive, objective predictors of embryo quality, such as it appears to be the case with the Eeva system, we will be able to transfer fewer embryos into the womb, not only leading to higher viable pregnancy rates, but also minimizing the chances for the establishment of high risk multiple pregnancies such as twins and triplets. In the end, this may prove to be the most important contribution from the development of methods for the non-invasive evaluation of embryo quality.”
In addition to VerMilyea and Coutifaris, other Penn authors are Monica Mainigi, MD and Joshua T. Anthony. Other fertility centers participating in the study were Pacific Fertility Center, Reproductive Science Center of the Bay Area, Palo Alto Medical Foundation Fertility, HRC Fertility and Stanford Fertility & Reproductive Medicine Center.
Editor’s note: Dr. VerMilyea has served as a consultant for Auxogyn, Inc. which provided the technology for the study.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.